It is important to note that a weight plateau does not mean treatment failure
If a patient decides they want to continue to use brand-name medication, most insurers will require them to pay out of pocket for the remaining balance
As demonstrated above, semaglutide (the active ingredient in Wegovy) leads to more clinically significant weight loss and blood sugar reductions than dulaglutide (the active ingredient in Trulicity)
Moreover, the phase I study of navoximod combined with the PD-L1 inhibitor, atezolizumab, also showed no significant benefit in the addition of navoximod (Jung et al., 2019)
Before signing a contract with a PBM, employers should evaluate which pricing arrangement works best for them
15 Questions to Score Your Organization's Benefit Program See what you are missing